Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Income (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Net Income for 15 consecutive years, with $27.5 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 367.86% to $27.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $78.4 million through Dec 2025, up 523.07% year-over-year, with the annual reading at $78.3 million for FY2025, 522.94% up from the prior year.
  • Net Income hit $27.5 million in Q4 2025 for Ani Pharmaceuticals, up from $26.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $27.5 million in Q4 2025 to a low of -$24.2 million in Q3 2024.
  • Historically, Net Income has averaged -$590600.0 across 5 years, with a median of -$1.1 million in 2021.
  • Biggest five-year swings in Net Income: plummeted 18370.0% in 2022 and later skyrocketed 1135.21% in 2024.
  • Year by year, Net Income stood at -$24.1 million in 2021, then skyrocketed by 82.24% to -$4.3 million in 2022, then surged by 126.99% to $1.2 million in 2023, then plummeted by 989.7% to -$10.3 million in 2024, then soared by 367.86% to $27.5 million in 2025.
  • Business Quant data shows Net Income for ANIP at $27.5 million in Q4 2025, $26.6 million in Q3 2025, and $8.5 million in Q2 2025.